Everything below concerns dual agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-22. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
=== Copyright claims === In response to a takedown notice from Nintendo in April 2024, Facepunch Studios began removing Nintendo-related Steam Workshop entries. Due to a large backlog, the studio asked community members to delete their relevant uploads to aid this process. Newman denied rumours that the notice was issued by a party unrelated to Nintendo, as had been the case in past instances. Newman received a takedown notice relating to the Skibidi Toilet web series in July 2024. The series's creator, DaFuq!?Boom!, argued that he wanted to subdue the spread of pornographic derivatives of his work.
Deep gas-phase reactor oxidation of ethylene oxide at 800–1,000 K (527–727 °C; 980–1,340 °F) and a pressure of 0.1–1 MPa (15–145 psi) yields a complex mixture of products containing O2, H2, CO, CO2, CH4, C2H2, C2H4, C2H6, C3H6, C3H8, and CH3CHO.
tryptophan to tryptamine phenylalanine to phenylethylamine tyrosine to tyramine histidine to histamine serine to ethanolamine glutamic acid to GABA lysine to cadaverine arginine to agmatine ornithine to putrescine 5-HTP to serotonin L-DOPA to dopamine Other decarboxylation reactions from the citric acid cycle include:
Sources: en.wikipedia.org
=== Provincial government === Yasir Naqvi, the Attorney General of Ontario, and Eric Hoskins, the province's Minister of Health and Long-Term Care, jointly announced on the day of Wettlaufer's sentencing that the provincial government would commission a public inquiry into her case. The full details of the inquiry were not given in the announcement, as the government had yet to determine the scope or an individual to lead the inquiry, with Naqvi and Hoskins instead saying that the inquiry would "get the answers we need to help ensure a tragedy such as this does not happen again." The delay in establishing the inquiry was criticized by members of the opposition Progressive Conservative and New Democratic parties toward the end of July 2017, as no progress had seemingly been made since the announcement and the Legislative Assembly had risen for its summer recess. The Public Inquiry into the Safety and Security of Residents in the Long-Term Care Homes System was formally established by the provincial government on August 1, 2017. Justice Eileen Gillese of the Court of Appeal for Ontario was appointed commissioner of the inquiry. The inquiry was to include interviews with victims' families and public consultations in the community as it investigated the circumstances surrounding the deaths of Wettlaufer's victims and gaps in legislative or policy frameworks that allowed her to continue working as a nurse. The inquiry's lead counsel stated that "anyone from Wettlaufer to Premier Kathleen Wynne" may be called to testify before the inquiry based on the evidence that is uncovered.
=== EC 1.17.4 With a disulfide as acceptor === EC 1.17.4.1: ribonucleoside-diphosphate reductase EC 1.17.4.2: ribonucleoside-triphosphate reductase (thioredoxin) EC 1.17.4.3: transferred to EC 1.17.7.1, (E)-4-hydroxy-3-methylbut-2-enyl-diphosphate synthase. EC 1.17.4.4: vitamin-K-epoxide reductase (warfarin-sensitive) EC 1.17.4.5: vitamin-K-epoxide reductase (warfarin-insensitive)
== Example == This is an example of an esterification reaction where one molecule acetic acid (also called ethanoic acid) reacts with one molecule ethanol, yielding one molecule ethyl acetate (a bimolecular second-order reaction of the type A + B → C):
== Molecular studies == A monophyletic Pancrustacea has been supported by several molecular studies, in most of which the subphylum Crustacea is paraphyletic with regard to hexapods (that is, that hexapods, including insects, are derived from crustacean ancestors). This means that within Pancrustacea, only some members are actually crustaceans, hexapods being the main exception. The evidence for this clade derives from molecular data and morphological characteristics. The molecular data consists of comparisons of nuclear ribosomal RNA genes, mitochondrial ribosomal RNA genes, and protein coding genes. The morphological data consists of ommatidial structures (see arthropod eye), the presence of neuroblasts, and the form and style of axonogenesis by pioneer neurons.
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.